Consolidated Statements of Non-Controlling Interest and Stockholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	Non-Controlling Interest [Member]	Non-Controlling Interest [Member] Silver Creek Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2016	$ (251,120)	$ (1,539)		$ 1,302	$ 702,377		$ (954,799)
Balance (in shares) at Dec. 31, 2016				13,020
Exercise of stock options	6,689			$ 32	6,657
Exercise of stock options (shares)				323
Consideration allocated to reacquisition of conversion feature on extinguishment of convertible notes due 2020	(4,481)				(4,481)
Dividend paid	(140,000)				(140,000)
Issuance of preferred stock by Silver Creek Pharmaceuticals, Inc.			$ 847
Stock-based compensation	13,168				13,168
Loss attributable to non-controlling interest	1,160	(1,160)					1,160
Deconsolidation of non-controlling interest		$ 1,852
Net income (loss)	470,868						470,868
Balance at Dec. 31, 2017	96,284			$ 1,334	577,721		(482,771)
Balance (in shares) at Dec. 31, 2017				13,343
Stock-based compensation	3,050				3,050
Unrealized loss on marketable securities	(9)					$ (9)
Net income (loss)	(40,506)						(40,506)
Balance at Dec. 31, 2018	$ 58,819			$ 1,334	$ 580,771	$ (9)	$ (523,277)
Balance (in shares) at Dec. 31, 2018				13,343